Microdosing in early lead discovery

Bioanalysis. 2010 Mar;2(3):421-8. doi: 10.4155/bio.09.189.


Microdosing provides a tool to enhance drug development by initiating human studies prior to Phase I studies. The purpose is to assist in the go versus no-go decision-making process and to eliminate early ineffective compounds from the drug pipeline. Selection of multiple potential leads can be performed at the clinical stage instead of in preclinical studies. The microdosing approach can be easily used for a molecularly targeted potential drug compound with a known mechanism of action. It provides useful data regarding accessibility and biodistribution that can be used in many estimations benefiting the development of the molecule. In addition, steady state and genetic investigations are becoming possible. Microdosing has a sparing effect on timelines and costs, however, the real importance is not yet known because, although it is known to be widely performed, only a few original reports have been published.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials, Phase I as Topic / ethics
  • Clinical Trials, Phase I as Topic / legislation & jurisprudence
  • Clinical Trials, Phase I as Topic / methods*
  • Drug Discovery / ethics
  • Drug Discovery / legislation & jurisprudence
  • Drug Discovery / methods*
  • Genetics
  • Government Regulation
  • Humans
  • Pharmacokinetics